XML 75 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Note 4 - Collaboration Revenue - Schedule of Collaboration Revenue (Details) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
	Nov. 20, 2020	Nov. 30, 2020	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair value of Series A-2 Preferred Shares (Note 14)			$ 0	$ 5,000	$ 0
SEED Therapeutics Inc. [Member] | Research Collaboration and License Agreement with Eli Lilly [Member]
Collaboration arrangement – research and development services	$ 9,455	$ 10,000
Fair value of Series A-2 Preferred Shares (Note 14)	5,267
Fair value of the Forward (Note 15)	278
Total cash proceeds	$ 15,000					$ 15,000

X

- Definition

The amount of upfront cash payment from collaborative arrangement.

+ References

No definition available.

+ Details

Name:	bysi_CollaborativeArrangementUpfrontCashPayment
Namespace Prefix:	bysi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the proceeds allocated to forward liability.

+ References

No definition available.

+ Details

Name:	bysi_ProceedsAllocatedToForwardLiability
Namespace Prefix:	bysi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The cash inflow from issuance of redeemable noncontrolling interests.

+ References

No definition available.

+ Details

Name:	bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests
Namespace Prefix:	bysi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

+ Details

Name:	us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	dei_LegalEntityAxis=bysi_SEEDTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: